Serologic laboratory findings in malignancy

Rheumatic Disease Clinics of North America

Volumn 37, Issue 4, 2011, Pages 507-525

  Madrid, Félix Fernández ^a   Maroun, Marie Claire ^a  

^a DETROIT RECEIVING HOSPITAL   (United States)

Author keywords

Antinuclear antibodies; Antiphospholipid antibodies; Autoantibodies; Autoimmunity; Cancer

Indexed keywords

ANNEXIN XI A ANTIBODY; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; DOUBLE STRANDED DNA ANTIBODY; P53 ANTIBODY; PHOSPHOLIPID ANTIBODY; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; BREAST CANCER; CANCER RELAPSE; CANCER SURVIVAL; DERMATOMYOSITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GENOMICS; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SENSITIVITY AND SPECIFICITY; SEROLOGY; SOLID TUMOR; SYSTEMIC LUPUS ERYTHEMATOSUS; VENOUS THROMBOEMBOLISM;

ANTIBODIES, ANTINUCLEAR; GENOMICS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PARANEOPLASTIC SYNDROMES; PROTEOMICS; SEROLOGIC TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 80755155755     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2011.09.006     Document Type: Review

References (149)

1. Burnham T.K. Antinuclear antibodies in patients with malignancies. Lancet 1972, 26:436.
2. Zuber M. Positive antinuclear antibodies in malignancies. Ann Rheum Dis 1992, 51:573-574.
3. Fernández Madrid F., Karvonen R.L., Kraut M.J., et al. Autoimmunity to collagen in human lung cancer. Cancer Res 1996, 56:21-126.
4. Fernández-Madrid F., VandeVord P.J., Yang X., et al. Antinuclear antibodies as potential markers of lung cancer. Clin Cancer Res 1999, 5:1393-1400.
5. Tomkiel J.E., Alansari H., Tang N., et al. Autoimmunity to the Mr 32,000 subunit of replication protein A in breast cancer. Clin Cancer Res 2002, 8:752-758.
6. Fernández Madrid F., Tomkiel J. Antinuclear antibodies as potential markers of lung cancer. Cancer and autoimmunity 2000, 151-158. Elsevier, Amsterdam. Y. Shoenfeld, M.E. Gershwin (Eds.).
7. Tan E.M. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest 2001, 108:1411-1415.
8. Tan E.M., Shi F.D., Keck W.M. Relative paradigms between autoantibodies in lupus and autoantibodies in cancer. Clin Exp Immunol 2003, 134:169-177.
9. Tan E.M. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989, 44:93-151.
10. Reichlin M. Systemic lupus erythematosus. The autoimmune diseases 1998, 283-298. Acad. Press, San Diego. 3rd edition. N.R. Rose, I.R. Mackay (Eds.).
11. Alspaugh M., Maddison P.J. Resolution of the identity of certain antigen-antibody systems in systemic lupus erythematosus and Sjögren's syndrome: an interlaboratory collaboration. Arthritis Rheum 1979, 22:796-798.
12. Von Mühlen C.A., Tan E.M. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995, 24:323-358.
13. Harley J.B. Autoantibodies in systemic lupus erythematosus. Arthritis and allied diseases. a text of rheumatology 1997, vol. 2:347-360. 13th edition. W.J. Koopman (Ed.).
14. Sahin U., Tureci O., Schmitt H., et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995, 92:11810-11813.
15. Chen Y.T. Identification of human tumor antigens by serological expression cloning: an online review on SEREX. Cancer Immunol 2004, Available at:, Accessed March, 2004. http://www.cancerimmunity.org/SEREX/.
16. Fernández-Madrid F., Tang N., Alansari H., et al. Autoantibodies to annexin XI-A and other autoantigens in the diagnosis of breast cancer. Cancer Res 2004, 64:5089-5096.
17. Fernández Madrid F. Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. Cancer Lett 2005, 230:187-198.
18. Chatterjee M., Mohapatra S., Ionan A., et al. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res 2006, 66:1181-1190.
19. Wang X., Yu J., Sreekumar A., et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005, 353:1224-1235.
20. Lin H.S., Talwar H.S., Tarca A.L., et al. Autoantibody approach for serum-based detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev 2007, 16:2396-2405.
21. Zhong L., Coe S.P., Stromberg A.J., et al. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol 2006, 1:513-519.
22. Hanash S. Disease proteomics. Nature 2003, 422:226-232.
23. Hanash S. Harnessing the immune response for cancer detection. Cancer Epidemiol Biomarkers Prev 2011, 20:569-570.
24. Zhang J.Y., Casiano C.A., Peng X.X., et al. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003, 12:136-143.
25. Storr S.J., Chakrabarti J., Barnes A., et al. Use of autoantibodies in breast cancer screening and diagnosis. Expert Rev Anticancer Ther 2006, 6:1215-1223.
26. Boyle P., Chapman C.J., Holdenrieder S., et al. Clinical validation of an autoantibody test for lung cancer. Ann Oncol 2011, 22:383-389.
27. Shoenfeld Y., Ben-Yehuda O., Napartstek Y., et al. The detection of a common idiotype of anti-DNA antibodies in the sera of patients with monoclonal gammopathies. J Clin Immunol 1986, 6:194-204.
28. Shoenfeld Y., El-Roeiy A., Ben-Yehuda O., et al. Detection of anti-histone activity in sera of patients with monoclonal gammopathies. Clin Immunol Immunopathol 1987, 42:250-258.
29. Abou-Shakrah M., Krupp M., Argov S., et al. The detection of anti-Sm-RNP activity in sera of patients with monoclonal gammopathies. Clin Exp Immunol 1989, 75:349-353.
30. Syrigos K.N., Charalambopoulos A., Pliarchopoulou K., et al. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res 2000, 20:4351-4353.
31. Lleo A., Invernizzi P., Gao B., et al. Definition of human autoimmunity-autoantibodies versus autoimmune disease. Autoimmun Rev 2010, 9:A259-A266.
32. Rugiene R., Dadoniene J., Aleknavičius E., et al. Prevalence of paraneoplastic rheumatic syndromes and their antibody profile among patients with solid tumours. Clin Rheumatol 2011, 30:373-380.
33. Racanelli V., Prete M., Minoia C., et al. Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev 2008, 7:352-358.
34. McCarty G.A. Autoimmunity and malignancy. Med Clin North Am 1985, 69:599-615.
35. Abu-Shakra M., Buskila D., Ehrenfeld M., et al. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 2001, 60:433-441.
36. Carsons S. The association of malignancy with rheumatic and connective tissue diseases. Semin Oncol 1997, 24:360-372.
37. Ehrenfeld M., Shoenfeld Y. Malignancies and autoimmune rheumatic diseases. J Clin Rheumatol 2001, 7:47-50.
38. Szekanecz Z., Szekanecz E., Bakó G., et al. Malignancies in autoimmune rheumatic diseases-a mini-review. Gerontology 2011, 57:3-10.
39. Dinarello C.A., Mier J.W. Lymphokines. N Engl J Med 1987, 317:940-945.
40. Nicolini A., Carpi A., Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev 2006, 17:325-337.
41. Smyth M.J., Cretney E., Kershaw M.H., et al. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004, 202:275-293.
42. Nzula S., Going J.J., Scott D.I. Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res 2003, 63:3275-3280.
43. De Visser K.E., Koretz L.V., Coussens L.M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2008, 7:411-423.
44. Hansen M.H., Nielsen H.V., Ditzel H.J. Translocation of an intracellular antigen to the antibody response elicited by tumor-infiltrating B cells. J Immunol 2002, 169:2701-2711.
45. Coronella-Wood J.A., Hersh E.M. Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother 2003, 52:715-738.
46. Johansson M., Denardo D.G., Coussens L.M. Polarized immune responses differentially regulate cancer development. Immunol Rev 2008, 222:145-154.
47. DeNardo D.G., Coussens L.M. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007, 9:212.
48. Chapman C.J., Murray A., McElveen J.E., et al. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 2008, 63:228-233.
49. Koziol J.A., Zhang J.Y., Casiano C.A., et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003, 9:5120-5126.
50. Brichory F., Beer D., LeNaour F., et al. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res 2001, 61:7908-7912.
51. Carlsson P., Olofsson S.O., Bondjers G., et al. Molecular cloning of human apolipoprotein B cDNA. Nucleic Acids Res 1985, 13:8813-8826.
52. Ekins R.P. Multi-analyte immunoassay. J Pharm Biomed Anal 1989, 7:155-168.
53. Robinson W.H., DiGennaro C., Hueber W., et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med 2002, 8:295-301.
54. Lee K.H. Proteomics: a technology-driven and technology-limited discovery science. Trends Biotechnol 2001, 19:217-222.
55. Ge H. UPA, a universal protein array system for quantitative detection of protein-protein, protein-DNA, protein-RNA and protein-ligand interactions. Nucleic Acids Res 2000, 28:e3.
56. Walter G., Büssow K., Cahill D., et al. Protein arrays for gene expression and molecular interaction screening. Curr Opin Microbiol 2000, 3:298-302.
57. Ekins R.P. Ligand assays: from electrophoresis to miniaturized microarrays. Clin Chem 1998, 44:2015-2030.
58. Lagarkova M.A., Koroleva E.P., Kuprash D.V., et al. Evaluation of humoral response to tumor antigens using recombinant expression-based serological mini-arrays. Immunol Lett 2003, 85:71-74.
59. Fernández Madrid F., Tang N., Alansari H., et al. Improved approach to identify cancer-associated autoantigens. Autoimmun Rev 2005, 4:230-235.
60. Fernández Madrid F., Chen W., Tang N., et al. Autoantibodies in breast cancer identify proteins involved in self-renewal and epigenetic chromatin remodeling. Open Biomarkers J 2010, 3:13-20.
61. D'Orsi C.J., Newell M.S. On the frontline of screening for breast cancer. Semin Oncol 2011, 38:119-127.
62. National Lung Screening Trial Research Team, Aberle D.R., Adams A.M., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011, 365:395-409.
63. Bei R., Masuelli L., Palumbo C., et al. A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: inflammation in their induction and impact on tumor growth. Cancer Lett 2009, 281:8-23.
64. Saif M.W., Zalonis A., Syrigos K. The clinical significance of autoantibodies in gastrointestinal malignancies: an overview. Expert Opin Biol Ther 2007, 7:493-507.
65. Whitehouse J.M., Holborow E.J. Smooth muscle antibody in malignant disease. Br Med J 1971, 4:511-513.
66. Wasserman J., Glas U., Blomgren H. Autoantibodies in patients with carcinoma of the breast. Clin Exp Immunol 1975, 19:417-422.
67. Imai H., Nakano Y., Ochs R.H., et al. Nuclear antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol 1992, 140:859-870.
68. Solans-Laqué R., Pérez-Bocanegra C., Salud-Salvia A., et al. Clinical significance of antinuclear antibodies in malignant diseases: association with rheumatic and connective tissue paraneoplastic syndromes. Lupus 2004, 13:159-164.
69. Friou G.J. Clinical application of a test for lupus globulin-nucleohistone interaction using fluorescent antibody. Yale J Biol Med 1958, 31:40-47.
70. Rondeel J.M. Immunofluorescence versus ELISA for the detection of antinuclear antigens. Expert Rev Mol Diagn 2002, 2:226-232.
71. Jitsukawa T., Nakajima S., Junka U., et al. Detection of anti-nuclear antibodies from patients with systemic rheumatic diseases by ELISA using HEp-2 cell nuclei. J Clin Lab Anal 1991, 5:49-53.
72. Keren D.F. Antinuclear antibody testing. Clin Lab Med 2002, 22:447-474.
73. Martins T.B., Burlingame R., von Muhlen C.A., et al. Evaluation of multiplexed fluorescent microsphere immunoassay for detection of autoantibodies to nuclear antigens. Clin Diagn Lab Immunol 2004, 11:1054-1059.
74. Li Q.Z., Karp D.R., Quan J., et al. Risk factors for ANA positivity in healthy persons. Arthritis Res Ther 2011, 13:R38.
75. Pisetsky D.S. Antinuclear antibodies in healthy people: the tip of autoimmunity's iceberg?. Arthritis Res Ther 2011, 13:109.
76. Ackerman L.S. Sex hormones and the genesis of autoimmunity. Arch Dermatol 2006, 142:371-376.
77. Cutolo M. Estrogen metabolites: increasing evidence for their role in rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 2004, 31:419-421.
78. Treurniet R.A., Bergitjk E.C., Baelde J.J., et al. Gender-related influences on the development of chronic graft-versus-host disease induced experimental lupus nephritis. Clin Exp Immunol 1993, 91:442-448.
79. Marriott I., Huet-Hudson Y.M. Sexual dimorphism in innate immune responses to infectious organisms. Immunol Res 2006, 34:177-192.
80. Libert C., Dejager I., Pinheiro I. The X chromosome in immune functions: when a chromosome makes a difference. Nat Rev Immunol 2010, 10:594-604.
81. Arbuckle M.R., McClain M.T., Rubertone M.V., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526-1533.
82. Frenkel K., Karkoszka J., Kato J., et al. Systemic biomarkers of cancer risk. Cancer Detect Prev 1996, 20:234.
83. Frenkel K., Karkoszka J., Glassman T., et al. Serum autoantibodies recognizing 5-hydroxymethyl-2'-deoxyuridine, an oxidized DNA base, as biomarkers of cancer risk in women. Cancer Epidemiol Biomarkers Prev 1998, 7:49-57.
84. Shiel W.C., Jason M. The diagnostic associations of patients with antinuclear antibodies referred to a community rheumatologist. J Rheumatol 1989, 16:782-785.
85. Gómez-Puerta J.A., Cervera R., Espinosa G., et al. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum 2006, 35:322-332.
86. Cervera R., Piette J.C., Font J., et al. Antiphospholipid syndrome: Clinical and immunological manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002, 46:1019-1027.
87. Zuckerman E., Toubi E., Dov Golan T., et al. Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy. Br J Cancer 1995, 72:447-451.
88. De Meis E., Monteiro R.Q., Levy R.A. Lung adenocarcinoma and antiphospholipid antibodies. Autoimmun Rev 2009, 8:529-532.
89. Armas J.B., Dantas J., Mendonça D., et al. Anticardiolipin and antinuclear antibodies in cancer patients-a case control study. Clin Exp Rheumatol 2000, 18:227-232.
90. Miesbach W., Scharrer I., Asherson R.A. High titres of IgM-antiphospholipid antibodies are unrelated to pathogenicity in patients with non-Hodgkin's lymphoma. Clin Rheumatol 2007, 26:95-97.
91. Lossos I., Bogomolski-Yahalom V., Matzner Y. Anticardiolipin antibodies in acute myeloid leukemia: prevalence and clinical significance. Am J Hematol 1998, 57:139-143.
92. Font C., Vidal L., Espinosa G., et al. Solid cancer, antiphospholipid antibodies, and venous thromboembolism. Autoimmun Rev 2011, 10:222-227.
93. Sène D., Piette J.C., Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev 2008, 7:272-277.
94. Ostrowski R.A., Robinson J.A. Antiphospholipid antibody syndrome and autoimmune diseases. Hematol Oncol Clin North Am 2008, 22:53-65.
95. Crawford L.V., Pim D.C., Bulbrook R.D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982, 30:403-408.
96. Caron de Fromentel C., May-Levin F., Mouriesse H., et al. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int J Cancer 1987, 39:185-189.
97. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000, 60:1777-1788.
98. Sionov R.V., Haupt Y. Apoptosis by p53: mechanisms, regulation, and clinical implication. Springer Semin Immunopathol 1998, 19:345-362.
99. Lane D.P. p53, guardian of the genome. Nature 1992, 358:15-16.
100. Winter S.F., Minna J.D., Johnson B.E., et al. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992, 52:4168-4174.
101. Cesare E., Previti M., Lombardo F., et al. Serum anti-p53 autoantibodies in patients with type 1 diabetes. Ann Clin Lab Sci 2001, 31:253-258.
102. Kovacs B., Patel A., Hershey J.N., et al. Antibodies against p53 in sera from patients with systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 1997, 40:980-985.
103. Fenton C.L., Patel A., Tuttle R.M., et al. Autoantibodies to p53 in sera of patients with autoimmune thyroid disease. Ann Clin Lab Sci 2000, 30:179-183.
104. Chauhan R., Handa R., Das T.P., et al. Over-expression of TATA binding protein (TBP) and p53 and autoantibodies to these antigens are features of systemic sclerosis, systemic lupus erythematosus and overlap syndromes. Clin Exp Immunol 2004, 136:574-584.
105. Maehara Y., Kakeji Y., Watanabe A., et al. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer 1999, 85:302-308.
106. Kressner U., Glimelius B., Bergstrom R., et al. Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer. Br J Cancer 1998, 77:1848-1851.
107. Werner J.A., Gottschlich S., Folz B.J., et al. p53 serum antibodies as prognostic indicator in head and neck cancer. Cancer Immunol Immunother 1997, 44:112-116.
108. Lenner P., Wiklund F., Emdin S.O., et al. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study. Br J Cancer 1999, 79:927-932.
109. Lubin R., Zalcman G., Bouchet L., et al. Serum p53 antibodies as early markers of lung cancer. Nat Med 1995, 1:701-702.
110. Yamauchi T., Naoe T., Kurosawa Y., et al. Autoantibodies to c-myc nuclear protein products in autoimmune disease. Immunology 1990, 69:117-120.
111. Doyle G.A., Bordeaux-Heller J.M., Coulthard S., et al. Amplification in human breast cancer of a gene encoding a c-myc mRNA binding protein. Cancer Res 2000, 60:2756-2759.
112. Ben-Mahrez K., Sorokine I., Thierry D., et al. Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients. Int J Cancer 1990, 46:35-38.
113. Donner P., Greiser-Wilke I., Moelling K. Nuclear localization and DNA binding of the transforming gene product of avian myelocytomatosis virus. Nature 1982, 296:262-269.
114. Mimori T., Ohosone Y., Hama N., et al. Isolation and characterization of the 80-kDa subunit protein of the human autoantigen Ku (p70/p80) recognized by antibodies from patients with scleroderma-polymyositis overlap syndrome. Proc Natl Acad Sci U S A 1990, 87:1777-1781.
115. Sigurgeirsson B., Lindelöf B., Edhag O., et al. Risk of cancer in patients with dermatomyositis or polymyositis. N Engl J Med 1992, 326:363-367.
116. Targoff I.N. Humoral immunity in polymyositis/dermatomyositis. J Invest Dermatol 1993, 100:116S-123S.
117. Love L.A., Leff R.L., Fraser D.D., et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis specific autoantibodies define useful homogeneous patient groups. Medicine 1991, 70:360-374.
118. Belizna C., Henrion D., Beucher A., et al. Anti-Ku antibodies: clinical, genetic and diagnostic insights. Autoimmun Rev 2010, 9:691-694.
119. Burgman P., Ouyang H., Peterson S., et al. Heat inactivation of Ku autoantigen: possible role in hyperthermic radiosensitization. Cancer Res 1997, 57:2847-2850.
120. Lieber M.R., Ma Y., Pannicke U., et al. The mechanism of vertebrate nonhomologous DNA end joining and its role in V(D)J recombination. DNA Repair (Amst) 2004, 3:817-826.
121. Foidart J.M., Abe S., Martin G.R., et al. Antibodies to type II collagen in relapsing polychondritis. N Engl J Med 1978, 299:1203-1207.
122. Rowley M.J., Williamson D.J., Mackay I.R. Evidence for local synthesis of antibodies to denatured collagen in the synovium in rheumatoid arthritis. Arthritis Rheum 1987, 30:1420-1425.
123. Tarkowski A., Klareskog L., Carlsten H., et al. Secretion of antibodies to types I and II collagen by synovial tissue cells in patients with rheumatoid arthritis. Arthritis Rheum 1989, 32:1087-1092.
124. Bhowmick N., Neilson E., Moses H. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337.
125. De Wever O., Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003, 200:429-447.
126. 2+/phospholipid-binding proteins, annexin family. J Biol Chem 1992, 267:8919-8924.
127. Erdile L., Wold M.S., Kelly T.J. The primary structure of the 32 kDa subunit of human replication protein A. J Biol Chem 1990, 265:3177-3182.
128. Seogerson L., Moldave K. Characterization of the interaction of aminoacyltransferase II with ribosomes. Binding of transferase II and translocation of peptidyl transfer ribonucleic acid. J Biol Chem 1968, 243:5354-5360.
129. Schneider J.A., Raeburn S., Maxwell E.S. Translocase activity in the aminoacyltransferase II fraction from rat liver. Biochem Biophys Res Commun 1968, 33:177-181.
130. Jorgensen C.S., Levantino G., Houen G., et al. Determination of autoantibodies to annexin XI in systemic autoimmune diseases. Lupus 2000, 9:515-520.
131. Misaki Y., Pruijn G.J., van derKemp A.W. The 56K autoantigen is identical to human annexin XI. J Biol Chem 1994, 269:4240-4246.
132. Garcia Lozano R., Gonzalez Escribano F., Sanchez Roman J., et al. Presence of antibodies to different subunit of replication protein A in autoimmune sera. Proc Natl Acad Sci U S A 1995, 92:5116-5120.
133. Alberdi F., Dadone J., Ryazanov A., et al. Cross-reaction of lupus anti-dsDNA antibodies with protein translation factor EF-2. Clin Immunol 2001, 98:293-300.
134. Talal N. Benign and malignant lymphoid proliferation in autoimmunity. Recent Results Cancer Res 1978, 64:288-291.
135. Anaya J.M., McGuff H.S., Banks P.M., et al. Clinicopathological factors relating malignant lymphoma with Sjogren's syndrome. Semin Arthritis Rheum 1996, 25:337-346.
136. Yeatman T.J., Updyke T.V., Kaetzel M.A., et al. Expression of annexins on the surfaces of non-metastatic and metastatic human and rodent cells. Clin Exp Metastasis 1993, 11:37-44.
137. Chetcuti A., Margan S.H., Russel P., et al. Loss of annexin II heavy and light chains in prostate cancer and its precursors. Cancer Res 2001, 61:6331-6334.
138. Brichori F.M., Misek D.E., Yim A.M., et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A 2001, 98:9824-9829.
139. Parmer T.G., Ward M.D., Yurkow E.J., et al. Activity and regulation by growth factors of calmodulin-dependent protein kinase III (elongation factor 2-kinase) in human breast cancer. Br J Cancer 1999, 79:59-64.
140. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
141. Alberto Mantovani A., Allavena P., Sica A. Cancer-related inflammation. Nature 2008, 454:436-444.
142. Franklin W.A., Gazdar A., Haney J., et al. Widely dispersed p53 mutations in respiratory epithelium. J Clin Invest 1997, 100:2133-2137.
143. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 1994, 367:645-648.
144. Sell S., Pierce G.B. Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest 1994, 70:6-22.
145. Wicha M.S., Liu S., Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res 2006, 66:383-390.
146. Eisenbarth G.S. Type I diabetes mellitus. N Engl J Med 1986, 314:1360-1368.
147. Fernando M.M., Stevens C.R., Walsh E.C., et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet 2008, 4:e1000024.
148. Sawcer S., Compston A. Multiple sclerosis: light at the end of the tunnel. Eur J Hum Genet 2006, 14:257-258.
149. Todd J.A. Genetic control of autoimmunity in type 1 diabetes. Immunol Today 1990, 11:122-129.